Availability of an ultra-short-course drug regimen capable of curing patients with tuberculosis in 2 to 3 mo would significantly improve global control efforts. Because immediate prospects for novel treatment-shortening drugs remain uncertain, we examined whether better use of existing drugs could shorten the duration of treatment. Rifapentine is a long-lived rifamycin derivative currently recommended only in once-weekly continuation-phase regimens. Moxifloxacin is an 8-methoxyfluoroquinolone currently used in second-line regimens.
Francesco Stellacci, Matteo Gasbarri, Yong Zhu
Christian Ludwig, Horst Pick, Stefanos Giannakis, Adrian Pulgarin, Jiahua Chen, Dominik Refardt, Jérémie Decker
Paul Joseph Dyson, Irina Sinenko, Roland Christopher Turnell-Ritson